Norway invests in health innovation, but the discussion on funding continues
Norway has major ambitions to become a leading nation in the development of the medicines of the future. Researchers, entrepreneurs, and investors point out that the country already has strong prerequisites, such as high expertise, good access to data, and a solid academic environment.
Despite this potential, there is disagreement over how the future health industry should be financed. Many players in the industry believe that Norway must take a clearer role in supporting the development of new medicines, so that the country not only provides talent but also retains the value nationally.
The challenge lies in the balance between public investment and private capital. While many see opportunities for growth, there is a concern that Norway is not willing to take the financial risk required to compete with international players.
The debate over who should pay for the health solutions of the future is now central. There is a broad consensus that Norway has the talent needed to succeed, but it remains to be seen which political and economic framework conditions will be chosen to ensure that Norway remains at the forefront of medical development.